Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Verma

Showing results (531-540 of 562) with videos related to

Pageof 57
Sort By:
JAMA Network Open|January 16, 2019
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung CancerEric D Brooks, Bing Sun, Lei Feng, et al.
JAMA Oncology|July 21, 2017
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 StudyJoe Y Chang, Vivek Verma, Ming Li, et al.
Nature Immunology|November 24, 2020
MEK inhibition reprograms CD8<sup>+</sup> T lymphocytes into memory stem cells with potent antitumor effectsVivek Verma, Nazli Jafarzadeh, Shannon Boi, et al.
Oncotarget|April 21, 2017
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cellsMuzafar A Macha, Satyanarayana Rachagani, Asif Khurshid Qazi, et al.
Journal of Radiosurgery and SBRT|August 18, 2020
Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapyJoseph A Miccio, Andrew Barsky, Sarah Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
Science Translational Medicine|May 11, 2022
Acute inflammatory response via neutrophil activation protects against the development of chronic painMarc Parisien, Lucas V Lima, Concetta Dagostino, et al.
Journal of the National Cancer Institute|July 28, 2019
Sex-Based Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, C David Fuller, Shalini Moningi, et al.
Journal for Immunotherapy of Cancer|September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapyHari Menon, Dawei Chen, Rishab Ramapriyan, et al.
Pageof 57

Showing results (531-540 of 562) with videos related to

Sort By:
Pageof 57
JAMA Network Open|January 16, 2019
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung CancerEric D Brooks, Bing Sun, Lei Feng, et al.
JAMA Oncology|July 21, 2017
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 StudyJoe Y Chang, Vivek Verma, Ming Li, et al.
Nature Immunology|November 24, 2020
MEK inhibition reprograms CD8<sup>+</sup> T lymphocytes into memory stem cells with potent antitumor effectsVivek Verma, Nazli Jafarzadeh, Shannon Boi, et al.
Oncotarget|April 21, 2017
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cellsMuzafar A Macha, Satyanarayana Rachagani, Asif Khurshid Qazi, et al.
Journal of Radiosurgery and SBRT|August 18, 2020
Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapyJoseph A Miccio, Andrew Barsky, Sarah Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
Science Translational Medicine|May 11, 2022
Acute inflammatory response via neutrophil activation protects against the development of chronic painMarc Parisien, Lucas V Lima, Concetta Dagostino, et al.
Journal of the National Cancer Institute|July 28, 2019
Sex-Based Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, C David Fuller, Shalini Moningi, et al.
Journal for Immunotherapy of Cancer|September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapyHari Menon, Dawei Chen, Rishab Ramapriyan, et al.
Pageof 57